NDAQ enters its June 10 earnings release having shed 6.5% in a week — a move that slightly underperforms most close peers but fits a broad sector pullback.
Options positioning has quietly turned more defensive into the print. The put/call ratio has edged up to 0.56, running almost 1.8 standard deviations above its 20-day average of 0.52. That is not an extreme reading by historical standards — the 52-week high sits near 1.25 — but the directional drift over the past two weeks is clear: buyers have been adding downside protection as the stock weakened. The broader peer group confirms the risk-off tone. MORN fell more than 7% on the week; MSCI dropped 6.4%; FDS led the group lower at just over 9%. SPGI and held up somewhat better, both off around 4%. NDAQ's 6.5% decline puts it toward the middle of that pack — neither a standout loser nor a relative safe haven.
Short sellers are not pressing the trade. NDAQ's short interest has fallen roughly 8% over the past month to just 1.2% of the free float — too small a position to read as a meaningful directional signal. The lending market reflects the same indifference: borrow availability is essentially unlimited, with shares to lend dwarfing current demand by a factor of thousands, and the cost to borrow has eased 37% week-on-week to just 0.33%. There is no squeeze pressure here, no building short thesis. The cautious tone is coming from options traders, not short sellers.
The real debate heading into the print centres on whether a 10% FY26E EPS decline is already fully absorbed in the valuation, or whether it still presents a risk. Bulls point to accelerating revenue from Market Services — up 14% year-over-year last quarter — and a 25% jump in Financial Crime Management Technology as evidence that the non-trading business is compounding steadily. The Adenza acquisition pipeline offers cross-sell optionality that the headline EPS number does not yet capture. Bears counter that weak IPO activity and soft trading volumes leave the company dependent on technology revenue ramp-up to offset a still-heavy debt load, with limited room for execution stumbles. Analyst opinion tilts positive on balance — Barclays carries an Overweight with a $114 target, Morgan Stanley sits Overweight at $116, and JP Morgan is Overweight at $101 — but the consensus rating is a Hold, reflecting a meaningful minority that sees the risk/reward as balanced at current levels near $87. The price-to-earnings multiple has compressed about 0.6 points over the past month, keeping valuation from looking stretched even after last quarter's 4% post-earnings pop.
The June 10 print will test whether the recurring technology and analytics revenue streams can sustain their growth trajectory at a pace that justifies holding the stock through a broader market rotation away from financial-data names.
See the live data behind this article on ORTEX.
Open NDAQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
